On October 29 is organized every year the World Psoriasis Day. What does this event involve ? What is it about ?
An international patient association event
Under the initiative of the International Federation of Psoriasis Association (IFPA), the World Health Organization gave its approval to organize a regular event to raise awareness about psoriasis. Since 2004, World Psoriasis Day is institutionalised as a yearly event dedicated to people affected by psoriasis or psoriatic arthritis. It is now observed in 50 countries worldwide.
This day aims at giving voices to people suffering from the disease around the world. The main goal driving this event, conceived by an international consortium of associations, is to make the national and international authorities realize that psoriasis is not taken seriously enough. This is all the more essential as the main organizer, the IFPA, is a famous advocate for the rights of people with psoriasis or psoriatic arthritis since 1971.
4 main objectives
As the IFPA explains, four main objectives can be defined:
The first goal consists of heightening awareness for two reasons : informing people affected by psoriasis that they are not alone in their situation, but also dismissing the myths on psoriasis, especially the wrong idea of a contagious disease. Second, the event is supposed to improved access to treatments by spurring healthcare systems, governments, doctors and health are professionals to enable psoriasis sufferers to access optimized and adapted therapy.
Another significant issue raised by the event is the need for an improved understanding of the disease. Indeed, it seems currently essential to inform psoriasis sufferers and the general public on the pathology so that everyone is able to discuss it openly in a climate of trust. Last, but not least, the importance of building a strong global community about psoriasis has to be pointed out. Gathering the largest possible number of psoriasis sufferers worldwide to express their concerns over their situation, in a single platform, is a key instrument to be heard by the most important decision-makers.
Campaign 2018 : Pso Serious
More specifically, association members involved in the World Psoriasis Day contribute each year to the organization of many activities:
- Free psoriasis assessment and consultations at hospitals
- Activities for children and youth
- Photo exhibitions with psoriasis-related themes
- Radio or TV interviews with patient leaders or medical experts
- Fundraising barbecues, get-togethers or concerts
- Outdoor yoga sessions for people with psoriasis
- Coverage of World Psoriasis Day by local or national media
- Awareness-raising walks or running events
- Free information events for the general public
- Lectures or seminars held by medical professionals
- Handing out flyers and brochures in public places
- Drawing competitions
- Sending out WPD postcards
Each year, a specific theme is set by the IFPA to establish a guiding principle uniting the relevant activities. In 2018, the them “Treat Psoriasis Seriously” will accompany the core messages of the information campaign. Besides, even if the campaign material is intended for members, any people interested in organising a World Psoriasis Day activity is welcome to contact the IFPA secretariat to obtain promotion material.
Make mentalities evolve
The campaign theme and the event itself emerge in a context in which psoriasis is still a social burden. “Patients with psoriasis often express frustration to me that they experience discrimination in public places and the work environment,” Dr. Joel Gelfand of the University of Pennsylvania in Philadelphia told Reuters Health in mid-September. “My patients tell me that they have been asked not to use a pool, feel embarrassed going to the hair salon or have been fired from jobs that require interaction with the public.” The survey he recently conducted, as part of a university research, points out the many stigma and discriminations psoriasis sufferers still have to face nowadays. The results of his study in the US context is indisputable : about 54 % of people said they wouldn’t want to date someone with psoriasis, 40 % said they wouldn’t want to shake hands, and 32 % said they wouldn’t want to have psoriasis patients in their homes. The most frequent stereotypes are that people with psoriasis are "insecure", "sick" and "unattractive". Also, a third of participants believe the myths that psoriasis only affects the skin and is not a serious disease.
This situation, however, is not unique to the United States. In the French context, for instance, another study carried out by Ipsos in 2015 (one of the main French polling firm) revealed that 20 % of French people think psoriasis is a contagious disease. Also, a third of the participants said they would be reluctant to kiss someone affected by psoriasis, and 44 % declared they would not be able to have sexual relations with them. In 2017, the same survey company published another inquiry showing the many difficulties psoriasis sufferers are confronted with in the field of employment and workplace integration. All these facts highlight a lingering reticence to normal behaviour towards psoriasis patients, which demonstrates a significant need for more social integration to overcome the discriminations of a misinformed society.
For more information on the event, please click here
- 2019/08/12 Focus on...Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...News from our SPIN Columbian members
- 2019/05/21 Focus on...SPIN2019 is now available on your screen!
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2019/04/17 Focus on...Do not miss Spin Congress 2019 highlights
News from the web office
- 2017/06/05PIN becomes SPIN - Skin Inflammation & Psoriasis International Network
- 2016/10/29PSO 2016 Congress - Webcasts Available!
- 2016/05/26PIN Survey on Phototherapy
- 2016/02/20PIN Study on Therapeutic Patient Education
- 2016/02/19World Directory of Psoriasis Medical Resources - February 2016 Update
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2018/07/16SPIN Symposium at the Spring continental meeting - Tehran, 25-27 April 2018
- 2018/02/222nd National Meeting of the Egyptian Society for Psoriasis
- 2018/02/211st Psoriasis Symposium - Sarajevo 2017
- 2017/06/2815th São Paulo Meeting of Psoriasis and Vitiligo
News from medical groups
- 2018/04/183rd Turkish National Psoriasis Symposium
- 2017/06/21Brazilian Center for Psoriasis Studies joins SPIN!
- 2017/06/21Costa Rica Psoriasis Group - Meet them!
- 2017/02/02Works of the 1st Senegalese Psoriasis Day published!
- 2016/07/29Swiss S1 Guidelines for Systemic treatment of psoriasis vulgaris
News from patients associations
- 2017/02/08France Psoriasis - 2016 World Psoriasis Day
- 2016/05/26Senegal Patients Association joins PIN!
- 2015/08/04Epidermia Greece: a new partner association of PIN
- 2015/08/01Canadian Association of Psoriasis Patients joins PIN!
- 2015/04/09AEPSO Argentina launches digital map to find people with psoriasis in the country
Recent publications on Psoriasis and Atopic Dermatitis
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat. 2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat. 2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep.. 2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)see on pubmed
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat. 2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem. 2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol. 2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)see on pubmed